NCT01871454

Safety of Pentoxifylline and Vitamin E With Stereotactic Ablative Radiotherapy (SABR) in Non-small Cell Lung Cancers

Effect of Pentoxifylline and Vitamin E in Preventing Radiation-induced Toxicity in the Treatment of Recurrent or New Primary NSCLC Using Stereotactic Ablative Radiotherapy in Patients Previously Treated With Thoracic Radiation

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 59 (estimated)
• Sponsor: University of Louisville · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objective of this prospective phase II protocol is to assess the toxicity and efficacy of pentoxifylline and SABR in the re-treatment of recurrent or new lung cancers

Conditions

• Non-small Cell Lung Cancers

Interventions

Type	Name	Description
RADIATION	stereotactic ablative radiotherapy (SABR)	standard of care radiation therapy
DRUG	Pentoxifylline	pentoxifylline

Timeline

• Start date: 2013-10-01
• Primary completion: 2025-12-01
• Completion: 2025-12-01
• First posted: 2013-06-06
• Last updated: 2024-02-07

Locations

1 site across 1 country: United States